Li-Ping Kang – InmunoES

Pterostilbene inhibits non-small cell lung cancer progression by activating the STING pathway and enhancing antitumor immune response

16 de October de 2025 by Li-Ping Kang

IntroductionNon-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, and current therapies often yield limited efficacy. This study investigated the antitumor potential and mechanisms of Pterostilbene (PTE), a natural stilbeno…

Breakthroughs in immune checkpoint therapy: overcoming NSCLC immune checkpoint therapy resistance with novel techniques

2 de September de 2025 by Li-Ping Kang

Immune checkpoint therapy has emerged as a revolutionary approach in the field of non-small cell lung cancer (NSCLC), offering new hope to patients with various malignancies. Despite its success, a significant proportion of patients exhibit primary or …